Efficacy and Safety of ES16001 in Patients With COVID-19

NCT05525182 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

706

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

DRUG: ES16001 40 mg
DRUG: ES16001 80 mg
DRUG: ES16001 160 mg
DRUG: Placebo

Sponsor

Genencell Co. Ltd.